Conversely our adjustment for under-testing (adjustment factor 2)

Conversely our adjustment for under-testing (adjustment factor 2) could over-estimate true incidence since it is possible that children who are not tested represent a different clinical spectrum of disease, making invalid the assumption that the proportion of influenza positive cases in the untested group is the same as in the this website tested group. We also did not make any adjustments for children readmitted to the same or different HA hospital with the same influenza infection and for possible nosocomial infections which could have led to an over-estimation of incidence. It is also likely that children with nosocomial influenza will have a longer length of stay, emphasising

that length of stay does not consistently reflect disease severity. We have also assumed that the adjustment factors derived from one institution, PWH, can be applied uniformly across all the HA hospitals, and that these factors are stable over time. Although PWH is one of the largest HA hospitals accounting for about 10% of all the public hospital paediatric admissions, it is possible that there may be differences in clinical practices, admission policies and laboratory services between PWH and other HA hospitals and also over time. Estimates of the incidence of influenza

that requires hospital admission were higher in children less than 5 years of age. Incidence per 100,000 person-years was particularly high for infants aged 2 months to below 6 months of age (1762) but lower in those below two months

of age (627). Overall these estimates are higher than our previous 1997–1998 estimates but similar Vandetanib manufacturer to other Hong Kong estimates. Although a higher positivity rate for influenza was noted during the 2009/10 influenza surveillance period when A(H1N1)pdm09 started to circulate, this could reflect a permissive admission policy rather than increased disease burden and/or severity. Our data support the recommendation that effective vaccination of pregnant women is likely to have a significant impact on reducing disease burden in young infants below 6 months of age hospitalised for influenza. The Statistics and Workforce Planning Department in the Strategy and Planning Division of the Hong because Kong Hospital Authority provided the paediatric hospitals admission dataset from the HA clinical data repository for this study. Contributors: All authors approved the manuscript. E.A.S.N., M.I., J.S.T., A.W.M., P.K.S.C., contributed to study design and data interpretation. M.I. was the principal investigator. L.A.S. undertook literature review and initial drafting of manuscript. E.A.S.N., S.L.C., M.I., S.K.L., W.G., contributed to data analysis and interpretation. E.A.S.N. wrote the manuscript and produced all figures. Funding: This study was funded by the World Health Organization as part of Project 49 of the United States of America Center for Disease Control and Prevention, Grant 5U50C1000748.

Type 1 diabetes mellitus is characterized by loss of the insulin-

Type 1 diabetes mellitus is characterized by loss of the insulin-producing beta cells of the islets of Langerhans in the pancreas leading to insulin deficiency. While type 2 diabetes mellitus is characterized by insulin resistance which may be combined with relatively reduced insulin secretion. The defective responsiveness of body tissues to insulin is believed to involve the insulin receptor. It is also most common type of diabetes. Type 2 diabetes has also been loosely defined as “adult onset” diabetes. As diabetes becomes more common throughout the world, cases of T2D are being observed in younger people. The majority of individuals with type 2 diabetes are either overweight

or obese. WHO predicts that by 2025, the number Dinaciclib supplier of diabetic people will increase to 300 million. The genes involved in this disease are poorly defined. Many genes are thought to

be involved in type 2 diabetes. These genes may show subtle variation in the gene ABT-888 in vivo sequence and may be extremely common. Many genetic variants have been convincingly and repeatedly found to associate with the disease, each of which confers only a small increase in risk, making causality difficult to prove and also limiting the prognostic and diagnostic potential of these individual variants.1 Type 2 diabetes (T2D) has long been attributed to a complex interaction between an individual’s genetic background and multiple environmental factors. The genetic contribution has been confirmed by twin, family and population studies. Dissecting the genetic architecture of a complex disease such as T2D is a rather challenging task. The genetic variants detected, represent common variants shared by a large number of individuals but with modest effects. Each risk Tolmetin allele increases risk of T2D only by a small percentage. Profiling genetic variation aims to

correlate biological variation (phenotype) with variation in DNA sequences (genotype). The ultimate goal of mapping genetic variability is to identify the single-nucleotide polymorphism (SNP) causing a monogenic disease or the SNPs that increase susceptibility to a polygenic disease. Approximately 10–12 SNP markers in genes like IGF2BP2, CDKAL1, TCF7L2 and PPRG have been used worldwide to determine the risk factor of T2D.2 Genes significantly associated with developing T2D, include TCF7L2, PPARG, FTO, KCNJ11, NOTCH2, WFS1, CDKAL1, IGF2BP2, SLC30A8, JAZF1, and HHEX and KCNJ11.3, 4, 5 and 6 In this study, 4 prominent mutations spanning across 4 genes were investigated for their link with diabetic condition in Western Indian resource population namely Insulin Hormone (INS), Insulin Receptor (INSR), Transcription factor 7-like 2 (TCF7L2) and peroxisome proliferator-activated receptor-gamma (PPARG). The study subjects were a part of an ongoing insulin resistance study being undertaken by Department of Life Sciences, University of Mumbai in association with Medical Genetics Study Centre, geneOmbio Technologies, India.

Purified protein was quantified using Coomassie Plus Protein Assa

Purified protein was quantified using Coomassie Plus Protein Assay Reagent (Pierce). The plasmid pCI-EαRFP was prepared by PCR cloning of the EαRFP coding

sequence from the previously described plasmid pTrcHisEαRFP [1] into the mammalian expression plasmid pCIneo (Promega). The plasmid pCI-EαGFP was created by PCR using pTrcHisEαGFP as template. The plasmid pCI-OVAeGFP expresses a cytosolic OVAeGFP fusion protein. HeLa cells were cultured in DMEM supplemented as described above and were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. To ensure that pCI-EαGFP- and pCI-EαRFP-expressed EαGFP and EαRFP proteins could be correctly processed and the Eα peptide surface displayed, we set up co-culture, cross-presentation assays using http://www.selleckchem.com/products/gsk1120212-jtp-74057.html transfected HeLa cells as a source of Eα antigen and B6 (I-E−/I-Ab+) BMDCs as APCs. Decitabine datasheet HeLa cells (obtained from ECACC) were seeded in chamber slides and transfected with pCI-EαGFP, pCI-EαRFP, or control plasmids pCIneo or pCI-OVAeGFP. 24 h post-transfection, B6 BMDCs prepared as described previously [14], were added and cells were co-cultured to allow DCs to acquire plasmid-expressed Ag. BMDC cultures typically contained 85–90% CD11c+ cells. 4 h later, LPS (from Salmonella equi-abortus, Sigma) was added to a final concentration

of 1 μg/ml to induce DC maturation. After 24 h co-cultured CD11c+ DCs were analysed for GFP and surface Y-Ae staining by flow cytometry and by immunofluorescence staining of cells seeded in chamber slides. Lymph node and spleen cell suspensions from TEa Tg mice were prepared as previously described [1]. The Eα peptide-specific Tg CD4 T cells were identified as CD4+Vβ6+Vα2+. B6 recipients received 0.5–1 × 106 Tg T cells in 0.2 ml intravenously in the lateral tail vein 1 day prior to immunisation. In some experiments Tg T cells were labelled with CFSE prior to adoptive transfer as previously described [15]. For EαGFP protein immunisation, different Rolziracetam doses (100 μg, 10 μg, 1 μg, 100 ng, 10 ng and 1 ng) diluted in PBS, were administered subcutaneously in the

neck scruff, each with 1 μg/dose LPS (S. equi-abortus, Sigma) as adjuvant. Control mice received PBS containing 1 μg LPS. LPS was added in order to activate APC and drive them from an antigen acquisitive to antigen presenting state as widely described in the literature. For intramuscular DNA immunisation mice received 50 μg plasmid DNA diluted in endotoxin-free PBS in a 50 μl final volume in both tibialis anterior (TA) muscles. At various times after EαGFP subcutaneous protein immunisation and subcutaneous DNA injection, cervical (CLN), brachial (BLN) and inguinal (ILN) lymph nodes were removed, macerated through Nitex mesh (Cadish and Sons, London, UK) and digested with 1 mg/ml Collagenase A (Sigma) and 10 μg/ml DNase A (Roche Diagnostics) in HBSS for 30 min at 37 °C.

21 Mechanisms of action of such herbicides are the denovo fatty a

21 Mechanisms of action of such herbicides are the denovo fatty acid biosynthesis pathway. 22 and 23 small molecule library screening Inhibition blocks the synthesis of phospholipids which is essential building block for cell membrane for growth. 24 Shutting down either activity of two catalytic activities, BC and CT should be sufficient to inhibit the overall reaction of the enzyme ACC by herbicides.

Disturbance in the polymerization process, absence of means of synthesizing malonyl-CoA, inhibition by mimicking palmitoyl-CoA, inhibition by bisubstrate analog, structural components of herbicides CoA esters are well studied alternatives for drug targeting using ACC. 25 and 26 Molecular docking studies has been carried for the above mentioned compounds using Molegro Virtual Docker[ Table 3]. Binding sites were identified at positions

95Gly, Asp78, Arg41 etc 27 further found surrounding first cavity in Molegro Virtual Docker. Flexible molecular docking results are found to be considerable when above stated compounds from three classes were docked in the active site of modeled 3D structure of Acetyl-CoA carboxylase (ACC) from J. curcas. Docking scores are produced in  Table 3 which clearly indicates appreciable inhibitory activity profile of compounds screened. Compounds are arranged in descending order of their docking rerank scores belonging to each class. Comparison of candidates in terms of better binding ability shows that Pinoxaden (Phenylpyrazole class) could interact with ACC most effectively (rerank = −81.436 and RMSD = 0.31) check details to inhibit it. Other three members of the same group also indicate better binding affinities towards ACC inhibition as compared to other two classes and their compounds. Quizalofop (Aryloxyphenoxypropionates class) found intermediate position in terms of rerank = −77.4055 crotamiton and RMSD = 1.713. Sethoxydim (Cyclohexanediones class) was found to have least inhibiting effect on ACC as compared to other two classes and their compounds with

rerank = −71.917 and RMSD = 0.424. Docking scores are mathematical calculations to quantify force-fields between binding site of receptors and interacting ligands. For qualitative discussion, we should identify participation of atoms and groups of ligand with those complimenting atoms and groups of receptor amino acids. In order to map qualitative aspects of molecular docking studies, we have noted various types of atomic and molecular interactions which are reproduced in Fig. 5, Fig. 6 and Fig. 7. Blue dotted lines depict H-bond while maroon dotted lines quote steric interactions. Electrostatic interactions are found absent in current docking studies. Functional characterization of a protein sequence is a frequent problem in biological world. Today’s scenario is focused in identification and exploration of functional knowledge of bio-molecule like protein.

79–1 58] in Uruguay to 2 29 [1 37–3 83] in China The pooled AOR

79–1.58] in Uruguay to 2.29 [1.37–3.83] in China. The pooled AOR for the all-country data was 1.61 [1.46–1.79]. Female participants were less

likely than males to live in a smoke-free home in most LMICs but associations were only significant in India, Bangladesh, Brazil, Poland, Russian Federation, Turkey, Ukraine and Egypt. Participants from urban settings in India, Thailand, China, Philippines, Viet Nam, Brazil and Egypt were significantly more likely to live in a smoke-free home compared with those from the rural settings. In contrast, participants from rural settings were significantly more likely Panobinostat order to live in a smoke-free home in Romania, Russian Federation and Ukraine. The likelihood of living in a smoke-free home significantly increased with increasing education level in India,

Bangladesh, Thailand, Philippines, Ukraine and Egypt. Non-smokers were consistently more likely to live in a smoke-free home than smokers. No association was observed between SLT use and living in a smoke-free home. This study utilized data from the first round of GATS, conducted in 15 LMICs between 2008 and 2011, to examine whether being employed in a smoke-free workplace is associated with living in a smoke-free home. this website We found positive associations in all of the 15 LMICs studied (13 out of 15 being statistically significant) in individual level country-specific analysis. The pooled estimate indicated that participants employed in a smoke-free workplace were 60% more likely to live in a smoke-free home compared with those that worked where smoking occurred. These findings are consistent with those from previous studies conducted in high income settings. Cheng et al. (2011) in a longitudinal study conducted in the USA suggested that living in smoke-free homes

was four to seven times more likely among those employed in a 100% smoke-free workplace (compared with those employed in workplaces where smoking occurred). Another longitudinal study found similar reductions in smoking at home after the introduction of comprehensive Mephenoxalone smoke-free policies in Ireland (85% to 80%; p = 0.002) and the UK (82% to 76%; p = 0.003) (Fong et al., 2006). An evaluation of the smoke-free policy introduced in New Zealand in 2004 suggested that SHS exposure at workplaces decreased from 20% to 8% and the proportion of smoke-free homes increased from 64% to 70% between 2003 and 2006 (Edwards et al., 2008). Article 8 of WHO Framework Convention on Tobacco Control (FCTC) requires parties to adopt and implement measures to reduce exposure to tobacco smoke in indoor workplaces, indoor public places, public transport and other public places (World Health Organization, 2003). However, disparities observed in the implementation and enforcement of Article 8 of FCTC in LMICs (World Health Organization, 2013b) suggest that these benefits are not being fully realized.

These individual differences have become apparent in rodent model

These individual differences have become apparent in rodent models selectively bred for specific traits. The Lewis and Fischer 344 rats

are rodents with heightened (Fischer 344) or attenuated (Lewis) HPA-axis reactivity, and have been shown to differ in a wide range of HPA-axis-related behavioral and physiological traits (Sternberg et al., 1992). Stohr and colleagues showed that PNS had differential effects in the Lewis and Fischer 344 rats. In Lewis rats, PNS improved acquisition of active avoidance, decreased immobility in the forced swim test, and reduced novelty-induced locomotion, whereas in Fischer 344 rats PNS had no effect in the active avoidance or forced swim test, and increased novelty-induced DNA Damage inhibitor locomotion (Stohr et al., 1998). Studies in rats selectively bred for High and Low anxiety traits suggest that PNS has opposite effects in anxious versus non-anxious rats. Rats bred for high anxiety traits became less anxious after PNS, whereas rats bred for low anxiety traits became more anxious (Bosch et al., 2006). In a similar fashion, rats selectively bred for low novelty seeking behavior were reported to show less anxiety than their controls, whereas those rats selectively bred for high novelty seeking behavior were not affected by PNS (Clinton et al., 2008). Taken together these studies

suggest that PNS may have opposite effects dependent on the genetic background selleck chemicals of the individual. In addition to the differences in anxiety traits or HPA-axis responsivity, the way a stressor is perceived may play an important role in effects of PNS. The stress-coping style of an individual Adenosine determines the behavioral and physiological response of an organism to stress. Two clear stress-coping phenotypes can be distinguished, the proactive and passive stress-coping styles. Behaviorally, proactive stress-copers are characterized

by active responses to stressors; they will attempt to modulate the environment to reduce the stress (Koolhaas et al., 1999). This proactive stress response is illustrated in rodents during a defensive burying test. In this test proactively coping rats will bury an electrified prod that is placed in their cage with saw dust in order to avoid a shock. In contrast, passive stress-copers respond to stress in a more inhibited manner. In the defensive burying test, passive rodents will sit as far away from the prod as possible to avoid being shocked (de Boer and Koolhaas, 2003). These stress-coping phenotypes are highly correlated with other behavioral responses. Proactive stress-coping individuals tend to show more aggression and impulsivity and are less behaviorally flexible than passive stress-copers (Coppens et al., 2010).

Further secondary outcomes were recovery expectation and pain sel

Further secondary outcomes were recovery expectation and pain self efficacy. Recovery expectation was measured using the same question used to determine eligibility, scored from 0 to 10 with a higher score indicating more positive expectations (Iles et al 2009). The minimum clinically important difference for this measure has not been established. Pain self efficacy was measured using the Pain

Self Efficacy Questionnaire, a measure of a person’s confidence to complete specific activities despite their current level of pain (Nicholas, 2007). The Pain Self Efficacy Questionnaire is scored out of a total of 60 points, with a higher score indicating a higher S3I-201 clinical trial level of pain self efficacy. The Pain Self Efficacy Questionnaire has good test-retest reliability over a 3-month period (r = 0.73) ( Nicholas, 2007) and sensitivity to change in patients with chronic low back pain ( Maughan and Lewis, 2010). The minimum clinically important difference for this measure is 11 points ( Maughan and Lewis, 2010). To achieve a power of 80% with 95% confidence to detect a clinically important difference

http://www.selleckchem.com/products/blz945.html of 2.0 points on the Patient Specific Functional Scale (Maughan and Lewis, 2010), assuming a standard deviation of 1.6 points similar to that found in other studies of non-specific low back pain (Stratford et al 1995), 24 participants were required (Buchner et al 2007). A target sample size of 30 was set to allow for some loss to follow up. Outcomes were analysed on an intention-to-treat basis for all available data. To compare the two groups on the primary and secondary outcomes, analysis of covariance (ANCOVA) was applied comparing the means Isotretinoin at 4 and 12 weeks using the baseline scores as covariates (Vickers and Altman, 2001). To evaluate the impact of the

intervention, effect sizes (standardised mean differences) were calculated by dividing the difference in post intervention means by the pooled standard deviation (Hedges g) ( Hedges and Olkin, 1985). An effect size of 0.2 was considered small, 0.5 a medium sized effect, and 0.8 or greater a large effect size ( Cohen, 1992). The primary non-leisure activity score from the Patient Specific Functional Scale was also analysed by calculating the absolute risk reduction and number needed to treat statistic by comparing the proportion in each group achieving a successful return to the specified activity (determined a priori as a score of 7 or higher out of 10 on the Patient Specific Functional Scale) at 12 weeks. Thirty participants were recruited from 185 people screened between January 2008 and March 2010. Four participants (2 from each group) could not be contacted to complete final outcome measures at 12 weeks. The final analysis consisted of 26 participants, 13 from each group. The flow of participants through the trial and reasons for loss to follow-up are illustrated in Figure 1.

It may be beneficial to select a discrete dengue outbreak, such a

It may be beneficial to select a discrete dengue outbreak, such as the recent outbreak in Martinique, and examine all the associated costs. This could then be more broadly applied to better understand the total costs of dengue. The indirect costs FDA approved Drug Library cell line that are typically unaccounted for include the cost of disruption to health care services (caused by the influx of dengue cases), and the cost of decreased tourism, shipping, transport, and commerce due to fears of the disease spreading. The impact of dengue on patients and their families is significant, both

economically and in terms of quality of life. The economic cost disproportionately falls on the poor, particularly in countries where most costs are covered by the patient. A study in Cambodia showed that patients with dengue cover, on average, 78% of the total cost and 63% of the direct medical cost [28]. In a study in Thailand, 47% of patients with dengue could not afford to visit a reputable medical provider, 14% could not afford treatment, and 17% had to borrow money to cover the cost of illness [29]. Other studies in Cambodia show how these costs are a continuing burden to the

poor [30], with the majority (62%) this website still unable to repay their debts up to one year later [31]. There is also a significant drop (>50%) in the quality of life of both children and adults with dengue, which does not return to baseline until 12–16 days after onset of illness which is almost twice the duration of fever [32]. To raise the profile of dengue among governments and global decision-makers, which will be essential to secure funding for vaccine through introduction, it will be necessary to publicise the full

extent of the human burden of dengue. The morbidity caused by dengue should be highlighted and attempts made to move the global focus away from simply considering mortality statistics. While the mortality statistics for dengue are lower than for some other diseases considered a global health priority, the human impact of dengue morbidity is profound and, if better conveyed, persuasive. In particular, the impact of dengue on communities and its psychological impact on patients and families are often ignored. Computational modelling is an additional tool to support the decision-making process. It has proven to be highly advantageous in dengue research, for example in mapping the movement of the dengue virus from urban centres [33] and identifying the causes of the upwards shift in the average age of patients with dengue in some countries [34]. Each dengue-endemic country should have the opportunity to run its own modelling programs, however both human (skilled technicians/programmers) and material (sufficient computational power) resources are currently lacking.

5 μm sections were cut using a microtome and mounted on poly-L-ly

5 μm sections were cut using a microtome and mounted on poly-L-lysine-coated slides. Slides were stained using the Sirius red staining protocol which allows the identification of eosinophils (Meyerholz, Griffin, Castilow, & Varga, 2009). The number of eosinophils was counted per field of view magnification. Four fields of view were counted per animal. Eosinophils were defined as cells demonstrating a cytoplasm

staining an intense red with dark bi-lobed nuclei. All lung function data were plotted as a percentage of baseline to take into account the individual differences in guinea-pig baseline sGaw values. To account for differences in the timing of allergen responses during the early (0–6 h) and late (6–12 h) phases, sGaw was also expressed as the peak bronchoconstriction, displayed as a histogram next to a time course plot. Results are plotted as the mean ± standard error of the mean (SEM). Student’s t-tests check details were used for the comparison of differences

between groups or data points. One way analysis of variance (ANOVA) followed by a Dunnett’s post-test was used when 2 or more groups were being compared to a control group. A p value less than 0.05 was considered significant. Fig. 1 represents the mean time-course changes in sGaw over 24 h following Ova challenge in conscious guinea-pigs sensitised and challenged with saline or protocols 1–6. The sensitisation and learn more challenge protocol previously used successfully in this laboratory (Evans et al., 2012 and Smith and

Broadley, 2007) was protocol 1, which consisted of sensitisation with 2 injections of 100 μg/ml Ova and 100 mg Al(OH)3, with subsequent 100 μg/ml Ova challenge. This resulted in an immediate significant reduction in sGaw (− 45.6 ± 6.2%), characteristic of an early asthmatic response (Fig. 1A). This bronchoconstriction did not return to saline-challenged levels until 2 h post-challenge. No further decreases in sGaw, characteristic of the late asthmatic response, were observed. Increasing the Ova challenge concentration to 300 μg/ml (protocol 2, Fig. 1B) increased the immediate bronchoconstriction (− 60.9 ± 2.1%), compared to protocol 1, which Unoprostone returned to baseline levels 4 h post-challenge. No late asthmatic response was observed. Increases in the Ova sensitisation concentration to 150 μg/ml (protocol 4) and the number of injections (protocol 3) did not alter the airway response (not shown). Increasing the Al(OH)3 adjuvant concentration to 150 mg (protocol 5, Fig. 1C) did not alter the size or duration of the early asthmatic response compared to protocol 4 but produced a late asthmatic response, characterised by a significant decrease in sGaw at 6 h (− 17.6 ± 4.6% compared to − 3.8 ± 4.2%). Increasing the time between Ova sensitisation and challenge, while returning to protocol 4 conditions (protocol 6, Fig.

Arrays were analysed on a PCS4000 ProteinChip Reader using the Pr

Arrays were analysed on a PCS4000 ProteinChip Reader using the Protein Chip software version 3.0.6 (Ciphergen Biosystems, Inc., BEZ235 nmr Fremont, CA). The protocol averaged 10 laser shots per pixel with a focus mass of 24,000 Da, a matrix attenuation of 1000 Da and a range of 0–200,000 Da. The All-in-1 Protein Standard II (BioRad) was analysed on an NP20 array using the same analysis protocol. The following peaks were identified in the resulting spectrum and used to create

an internal calibration: hirudin BHVK (6964.0 Da), bovine cytochrome c (12230.92 Da), equine cardiac myoglobin (16951.51 Da) and bovine carbonic anhydrase (29023.66 Da). This internal calibration was applied to the spectra as an external calibration. The presented data are baseline subtracted and normalized by total ion current. Peaks with a signal-to-noise (S/N) ratio below 7 were not considered in subsequent analysis. FMDV antigen concentrated by PEG6000 precipitation is normally used for LBH589 clinical trial vaccine preparation. Such crude antigen preparations contain many proteins, most of

which are presumably derived from the BHK-21 cells used for virus propagation, as can be revealed by SDS-PAGE analysis (Fig. 1) of strains O1 Manisa (lane 2), Asia 1 Shamir (lane 4) and A24 Cruzeiro (lane 6). When the FMDV antigen of these strains is further purified by ultracentrifugation through a sucrose cushion it predominantly consists of three proteins migrating at about 23–25 kDa (Fig. 1, lanes 3, 5 and 7) which presumably represent VP1, VP2 and VP3. To facilitate the identification of the spectral peaks corresponding to the FMDV structural proteins

we used these purified antigens in SELDI-TOF-MS analysis employing NP20 arrays, which binds all proteins (Fig. 2a–c). The spectral peaks found were compared to the molecular masses predicted by translation of the RNA sequences (Table 1). For all three strains the peak at 9.0 kDa corresponds to myristoylated VP4, the peak at 23.2–23.3 kDa corresponds to VP1 and the peak at 24.5–24.9 kDa corresponds to VP2. Since these peaks are quite broad an accurate determination of their molecular mass is difficult. The molecular mass of VP3 is predicted to be intermediate between VP1 and VP2 (Table 1). A peak corresponding Astemizole to VP3 is more difficult to identify. Only in the profile of strain O1 Manisa a small peak can be seen at 24.1 kDa that could represent VP3 (Fig. 2c). The peak at 48 kDa that is observed with strain O1 Manisa but not with the two strains of other serotypes corresponds quite well to a VP1–VP2 dimer (Fig. 2c). For each serotype we also observe peaks of lower height at a normalized mass (m/z) of about 11.6 and 12.2 kDa, which is half the molecular mass of VP1 and VP2, and therefore represents double protonated forms of these proteins. For all three strains a repetitive pattern of peaks that differ by about 24 kDa is present in the molecular range above 50 kDa.